Evo Fund, a Cayman Islands investment vehicle, now holds 20.45% of Architects Studio Japan (TSE: 6085), down from 21.50% in its previous report. The change comes from a large-shareholding change report (No. 3), filed jointly with Evolution Capital Management LLC on 18 November, with an obligation date of 11 November 2026.
What the holding is made of
The 20.45% rests on 29.21mn shares and share equivalents: 5.5mn ordinary shares plus 23.71mn shares' worth of Series 5 warrants. The ratio is measured against 119,150,220 shares outstanding as of 11 November, adjusted for the warrant shares. Evolution Capital Management, the US co-filer, reports zero in its own right. It lists its purpose as pure investment under a discretionary investment mandate.
Under Japanese rules, a holder above 5% must file a change report when its ratio moves by 1 percentage point or more. Here the cover cites a drop of at least that size, at both the joint and the single-filer level.
Warrants in, shares out
The 60-day trading table lists the transactions behind the filing. On 28 September Evo Fund borrowed 5.7mn shares from an individual. On 14 October it acquired Series 5 warrants covering 28mn shares, at a reported unit price of 0.15.
From 16 October to 11 November it exercised warrants in lots of 50,000 to 700,000 shares, at unit prices that fell from 92 to 58. The report gives no reason for the lower prices. Over the same stretch it sold shares on the market in lots of 20,000 to 460,000, with a few small off-market disposals.
Exercise commitments in the purchase agreement
The report also summarises the 28 September purchase agreement between Architects Studio Japan and Evo Fund for the third-party allotment of the warrants. Evo Fund agreed to exercise warrants equal to 3.5mn shares by 25 December 2026, and warrants equal to 11.2mn shares by 10 February 2027. The commitment period can be extended under certain conditions, and the commitment lapses if specified conditions are met.
The agreement gives the company the right to set periods during which Evo Fund is barred from exercising designated Series 5 warrants. Evo Fund also agreed not to exercise more than the number the company specifies when certain conditions exist, and to obtain the board's prior written consent before transferring the warrants.
Purpose and funding
Evo Fund states its purpose as pure investment, with no specific situation anticipated. It says it may from time to time give the company advice as circumstances warrant, and it reports no important proposals. Its own funds total ¥3.56mn, and the borrowed 5.5mn shares are listed separately.
